INJECTAFER® Approved in the U.S. for the Treatment of Iron Deficiency in Adult Patients with Heart Failure

INJECTAFER is now the first and only intravenous iron replacement therapy indicated for adult patients with heart failure who have iron deficiency


... | June 5, 2023

Related Keywords

Bridgewater ,New York ,United States ,Ohio ,American ,Ravi Tayi ,Daiichi Sankyo ,Drug Administration ,Daiichi Sankyo Group ,European Union ,Innovative Global Healthcare Company ,Luitpold Pharmaceuticals Inc ,Adverse Drug Events To American Regent Inc ,Pharmaceuticals Inc ,American Heart Association ,York Heart Association ,Allergan ,American Regent Inc ,Daiichi Sankyo Inc ,Pharmacosmos Therapeutics Inc ,Sustainable Development Of Society ,Laboratory Test Alterations ,York Heart Association Functional Classification ,American Regent ,New York Heart Association ,Chief Medical Officer ,Daiichi Sankyo Access Central ,Safety Information ,Iron Deficiency ,Heart Failure ,Adverse Drug Events ,Prescribing Information ,Global Healthcare Company Contributing ,Sustainable Development ,Stroke Statistics ,Card Fail ,Current Concepts ,Heart Failure Demand Assessment ,Outpatient Setting Working Meeting ,Basking Ridge ,American Heart ,Integrated Summary ,Periodic Safety Update Report ,Pharma Annual ,Daiichi Sankyo Co ,Td Stock Exchange ,News ,Information ,Press Release ,Injectafer ,Us ,Dow ,The ,First ,End ,Only ,Intravenous ,Iron ,Replacement ,Therapy ,Syndicated ,Or ,Adult ,Patients ,Ith ,Heart ,Failure ,Who ,Wave ,Ron 4568 Jp3475350009 ,